



## Press Release

January 29, 2018

Strides Shasun Limited  
(Formerly Strides Arcolab Limited)  
Strides House, Bannerghatta Road,  
Bangalore – 560076.

---

# Strides Shasun receives USFDA Approval for Tenofovir Disoproxil Fumarate Tablets

Product to be launched immediately

---

**Bangalore, January 29, 2018**, Strides Shasun Limited today announced that its wholly owned subsidiary Strides Pharma Global Pte. Ltd. has received approval for **Tenofovir Disoproxil Fumarate Tablets, 300 mg** from the United States Food & Drug Administration (USFDA). Tenofovir Disoproxil Fumarate tablet is a generic version of Gilead's Viread Tablet®, for which the patent expired on 25 January 2018. Strides is launching the product immediately. The company already had a tentative approval for the product from USFDA for supplying under U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program and was able to obtain expedited review of its ANDA application. It is among the first wave of companies launching the product in the US market, after the patent expiry.

According to IMS data, the US market for **Tenofovir Disoproxil Fumarate** is approximately USD 750 Million. The product will be manufactured at the company's Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market.

### **About Tenofovir Disoproxil Fumarate Tablets**

Tenofovir Disoproxil Fumarate Tablets is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. Tenofovir Disoproxil Fumarate Tablets is also indicated for the treatment of chronic hepatitis B in adults.

### **About Strides Shasun**

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has three business verticals, viz., Regulated Markets, Emerging Markets and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 9 manufacturing facilities spread across three continents including 7 US FDA approved facilities and 2 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at [www.stridesarco.com](http://www.stridesarco.com)

**For further information, please contact:**

<p><u>Strides</u></p> <p>Shashank Sinha, Managing Director +91 80 6784 0335</p> <p><u>Investors:</u></p> <p>Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791</p> <p>Strides Shasun Limited CIN : L24230MH1990PLC057062 Regd. Office: 201, 'Devavrata', Sector – 17, Vashi, Navi Mumbai – 400 703 Email: <a href="mailto:investors@stridesshasun.com">investors@stridesshasun.com</a></p>	<p><u>PR Consultancy</u></p> <p>Fortuna PR K Srinivas Reddy: +91 9000527213 <a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a></p> <p>K Priya: +91 9535425418 <a href="mailto:priya@fortunapr.com">priya@fortunapr.com</a></p>
---	--